Kshetry Arjun Ojha, Pant Narayan Dutt, Bhandari Raju, Khatri Sabita, Shrestha Krishma Laxmi, Upadhaya Shambhu Kumar, Poudel Asia, Lekhak Binod, Raghubanshi Bijendra R
Department of Microbiology, Goldengate International College, Battisputali, Kathmandu, Nepal.
Department of Microbiology, Grande International Hospital, Dhapasi, Kathmandu, Nepal.
Antimicrob Resist Infect Control. 2016 Jul 21;5:27. doi: 10.1186/s13756-016-0126-3. eCollection 2016.
Methicillin resistant Staphylococcus aureus (MRSA) has evolved as a serious threat to public health. It has capability to cause infections not only in health care settings but also in community. Due to the multidrug resistance shown by MRSA, there are limited treatment options for the infections caused by this superbug. Vancomycin is used as the drug of choice for the treatment of infections caused by MRSA. Different studies from all around the world have documented the emergence of strains of S. aureus those are intermediate sensitive or resistant to vancomycin. And recently, there have been reports of reduced susceptibility of MRSA to vancomycin, from Nepal also. So the main purpose of this study was to determine the minimum inhibitory concentration (MIC) of vancomycin to methicillin resistant S. aureus isolated from different clinical specimens.
Total 125 strains of S. aureus isolated from different clinical samples at KIST Medical College and Teaching Hospital, Lalitpur, Nepal from Nov 2012 to June 2013, were subjected to MRSA detection by cefoxitin disc diffusion method. The minimum inhibitory concentrations of vancomycin to confirmed MRSA strains were determined by agar dilution method. Yellow colored colonies in mannitol salt agar, which were gram positive cocci, catalase positive and coagulase positive were confirmed to be S. aureus.
Among, total 125 S. aureus strains isolated; 47(37.6%) were MRSA. Minimum inhibitory concentrations of vancomycin to the strains of MRSA ranged from 0.125 μg/ml to 1 μg/ml.
From our findings we concluded that the rate of isolation of MRSA among all the strains of S. aureus isolated from clinical samples was very high. However, none of the MRSA strains were found to be vancomycin intermediate-sensitive or vancomycin-resistant.
耐甲氧西林金黄色葡萄球菌(MRSA)已演变成对公共卫生的严重威胁。它不仅能够在医疗机构引发感染,还能在社区中传播。由于MRSA表现出多重耐药性,针对这种超级细菌引起的感染,治疗选择有限。万古霉素被用作治疗由MRSA引起的感染的首选药物。世界各地的不同研究都记录了对万古霉素中度敏感或耐药的金黄色葡萄球菌菌株的出现。最近,尼泊尔也有关于MRSA对万古霉素敏感性降低的报道。因此,本研究的主要目的是确定万古霉素对从不同临床标本中分离出的耐甲氧西林金黄色葡萄球菌的最低抑菌浓度(MIC)。
2012年11月至2013年6月期间,从尼泊尔拉利特布尔KIST医学院和教学医院的不同临床样本中分离出的总共125株金黄色葡萄球菌,采用头孢西丁纸片扩散法进行MRSA检测。通过琼脂稀释法测定万古霉素对确诊的MRSA菌株的确最低抑菌浓度。在甘露醇盐琼脂中呈黄色的菌落,为革兰氏阳性球菌,过氧化氢酶阳性且凝固酶阳性,被确认为金黄色葡萄球菌。
在总共分离出的125株金黄色葡萄球菌菌株中,47株(37.6%)为MRSA。万古霉素对MRSA菌株的最低抑菌浓度范围为0.125μg/ml至1μg/ml。
从我们的研究结果得出结论,从临床样本中分离出的所有金黄色葡萄球菌菌株中,MRSA的分离率非常高。然而,未发现任何MRSA菌株对万古霉素呈中度敏感或耐药。